Paxlovid Pharmacist Survey

Back to list

Paxlovid Pharmacist Survey

The following information has been shared on behalf of the Ministry of Health

Pharmacists are invited to take this short survey about assessing, dispensing and monitoring adverse events of nirmatrelvir/ritonavir (Paxlovid). Pharmacists are eligible to claim fees for clinical assessment (PAX-A) and for follow-up and monitoring of patients who received Paxlovid (PAX-F). Your input will help us evaluate this service and may be used to inform future initiatives.

This survey will take about 5 minutes to complete.

Take the Survey


The survey closes on, December 31, 2022


Oct 28, 2022